10-K/A: MIRA Pharmaceuticals Files Amendment No. 2 to Form 10-K/A to Include Exhibit 23.2
Form 10-K/A Amendment
MIRA Pharmaceuticals files an amendment to its annual report on Form 10-K to include the consent of Salberg & Company P.A.
Summary
- MIRA Pharmaceuticals, Inc. filed Amendment No. 2 on Form 10-K/A to its annual report for the fiscal year ended December 31, 2024.
- The sole purpose of this amendment is to include Exhibit 23.2, the consent of Salberg & Company P.A., to the exhibits included in the Annual Report.
- No other changes have been made to the original filing, and the amendment does not modify or update any financial or other information contained in the original filing.
- The amendment includes new certifications by the Registrant's principal executive officer and principal financial officer.
- As of March 28, 2025, there were 16,813,654 shares of common stock outstanding.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing, indicating the company is compliant with SEC regulations. This is generally viewed neutrally to positively.
Positives
- The company is fulfilling its filing requirements with the SEC.
- The CEO and CFO have certified the accuracy of the report.
Industry Context
This is a standard regulatory filing for a publicly traded company.
Key Dates
| Date | Description |
|---|---|
| 2023-07-28 | Date of Form S-1 filing (incorporated by reference for several exhibits) |
| 2023-08-07 | Date of Current Report on Form 8-K filing (incorporated by reference for Representatives Warrant) |
| 2023-08-12 | Date of Form S-3 filing (incorporated by reference for At The Market Agreement) |
| 2023-08-31 | Date of Current Report on Form 8-K filing (incorporated by reference for Amendment to Employment Agreement) |
| 2023-11-20 | Date of Current Report on Form 8-K filing (incorporated by reference for Common Stock Purchase Warrant and Exclusive License Agreement) |
| 2024-04-01 | Date of Form 10-K filing (incorporated by reference for Policy Relating to Recovery of Erroneously Awarded Compensation) |
| 2024-06-28 | Date of Current Report on Form 8-K filing (incorporated by reference for Amended and Restated Employment Agreement) |
| 2024-06-30 | Date used for calculating the aggregate market value of voting and non-voting common equity held by non-affiliates |
| 2024-08-13 | Date of Form 10-Q filing (incorporated by reference for Amendment to Employment Agreement) |
| 2024-12-31 | Fiscal year end date |
| 2025-03-28 | Original Filing Date of the Annual Report on Form 10-K |
| 2025-03-28 | Date of Salberg & Company P.A.'s report included in the Annual Report on Form 10-K |
| 2025-03-28 | Date as of which the number of outstanding shares of common stock is reported (16,813,654 shares) |
| 2025-04-16 | Date of Salberg & Company, P.A.'s consent |
| 2025-04-17 | Date of signatures for the Form 10-K/A |
Keywords
Form 10-K/A, Amendment, Annual Report, MIRA Pharmaceuticals, Salberg & Company, Financial Reporting, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.